FDA Fine Tunes Guidance Disclaimers, May Undertake Broad Review
Executive Summary
FDA is considering undertaking a broad guidance clean-up effort, agency Chief Counsel Daniel Troy indicated May 16 during a Generic Pharmaceutical Association legal symposium in Washington, D.C